Dachaigh › Lymphoma Burkitt › Ohio

Sgrùdaidhean clionaigeach Lymphoma Burkitt ann an Ohio

Tha 18 sgrùdaidhean airson Lymphoma Burkitt a’ lorg phàirtichean aig làraichean ann an Ohio.

Bailtean ann an Ohio

Teacsa sgrùdaidh oifigeil (Beurla)

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati

A’ fastadhÌre 3

Aoisean 1 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07223021

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Cincinnati Children's Hospital, Cincinnati

A’ fastadhÌre 1

Aoisean 0 gu 18 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06173518

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
agus 3 a bharrachd

A’ fastadhÌre 2

366 Days – 46 Years · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Case Western Reserve University, Cleveland
Cleveland Clinic Foundation, Cleveland
agus 2 a bharrachd

A’ fastadhÌre 3

Aoisean 18 gu 39 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT03150693

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Cincinnati Children's Hospital Medical Center, Cincinnati

A’ fastadhSgrùdadh amharc

Aoisean 0 gu 38 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06131801

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Cancer Center-West Chester, West Chester

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
agus 2 a bharrachd

A’ fastadhÌre 2

365 Days · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

University of Cincinnati Medical Center, Cincinnati

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
agus 3 a bharrachd

A’ fastadhÌre 2

Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
agus 4 a bharrachd

A’ fastadhÌre 3

365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

A’ fastadhÌre 2

Aoisean 7 gu 25 · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

The Ohio State University Wexner Medical Center, Columbus

A’ fastadhÌre 1/2

Aoisean 13 gu 90 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06533579

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital, Columbus
Ohio State University Comprehensive Cancer Center, Columbus

A’ fastadhÌre 1

Aoisean 2 agus nas sine · Gach gnè · Air ùrachadh 29 Cèit 2026 · NCT05418088

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Cleveland Clinic Foundation, Cleveland

A’ fastadhÌre 2

Aoisean 18 gu 54 · Gach gnè · Air ùrachadh 17 Màrt 2026 · NCT06918431

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

A’ fastadhÌre 1

Aoisean 1 gu 39 · Gach gnè · Air ùrachadh 18 Gearr 2026 · NCT06863259

Study of SGR-1505 in Mature B-Cell Neoplasms

Gabrail Cancer & Research Center, Canton
The Ohio State University - The James Cancer Hospital, Columbus

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gearr 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Cleveland Clinic, Cleveland

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Samh 2025 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

University of Cincinnati, Cincinnati

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Samh 2024 · NCT06034275

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.